Entrectinib (Rozlytrek) manufacturer and usage instructions detailed

Entrectinib (Rozlytrek, Chinese trade name Luo Shengquan), this innovative targeted therapy drug developed by Roche Genentech, has brought new treatment prospects to patients with tumors with specific genetic mutations. It is mainly used to treat ROS1positive adult metastatic non-small cell lung cancer. The drug is also indicated for the treatment of adult and pediatric patients 1 month and older with solid tumors that harbor neurotrophic tyrosine receptor kinase (NTRK) gene fusions, have no known acquired resistance mutations, are metastatic or where surgical resection may result in significant morbidity, and have progressed after treatment or for which there are no satisfactory alternative therapies.

With its potent and selective inhibitory ability, Entrectinib precisely blocks the activity of TRK (tropomyosin receptor kinase) and ROS1 (a receptor tyrosine kinase encoding), thereby effectively inhibiting the growth and spread of tumor cells. In particular, entrectinib has the unique ability to cross the blood-brain barrier, which makes it a significant advantage in the treatment of primary and metastatic brain diseases.

Regarding the correct use of entrectinib, patients must strictly follow medical instructions. First of all, entrectinib should be administered orally, and the tablets should be swallowed as whole as possible without chewing or crushing to ensure the efficacy and dose control of the drug. For patients with dysphagia, it should be used under the guidance of a doctor.

The recommended dose for adult patients is 600 mg once daily until disease progression or unacceptable toxicity. The dosage for pediatric patients is adjusted based on body surface area and should be used under the guidance of a physician experienced in anti-cancer treatment. During the treatment process, patients should regularly monitor their physical condition and consult their doctor promptly if they have any discomfort or questions.

In addition, entrectinib may interact with certain drugs. Therefore, patients should inform their doctors about all the drugs they are taking before taking them, including prescription drugs, over-the-counter drugs, health products, and Chinese herbal medicines. Particularly when used concomitantly with CYP3A inhibitors or inducers, the dose of entrectinib may need to be adjusted or concomitant use avoided. Also, patients should avoid grapefruit products because grapefruit may interact with entrectinib and cause unwanted side effects.

In summary, entrectinib (Rozlytrek/Rozlytrek), as an innovative drug from Roche Genentech, brings new treatment hope to patients with tumors with specific genetic mutations. However, correct use of medications is critical to ensure efficacy and patient safety. Therefore, patients must follow medical instructions when using entrectinib and maintain close communication with their doctors during treatment. At the same time, there are original drugs and affordable Lao version of generic drugs on the market. Patients can choose according to their needs, but they must make sure to choose formal channels to purchase.